Iron-deficiency anemia

New England Journal of Medicine

Volumn 372, Issue 19, 2015, Pages 1832-1843

  Camaschella, Clara ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ASCORBIC ACID; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRITIN; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; FERUMOXYTOL; HEMOGLOBIN; HEPCIDIN; IRON DEXTRAN; IRON ISOMALTOSE; IRON SACCHARATE; IRON SALT; TRANSFERRIN; IRON;

ALLERGIC REACTION; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; ATROPHIC GASTRITIS; AUTOSOMAL RECESSIVE DISORDER; BACKACHE; BARIATRIC SURGERY; CANCER CHEMOTHERAPY; CELIAC DISEASE; CHRONIC KIDNEY DISEASE; CONSTIPATION; DRUG WITHDRAWAL; FECES COLOR; FLUSHING; GLUTEN FREE DIET; HEADACHE; HEART FAILURE; HELICOBACTER INFECTION; HUMAN; INFLAMMATORY BOWEL DISEASE; IRON ABSORPTION; IRON BALANCE; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON REFRACTORY IRON DEFICIENCY ANEMIA; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; METALLIC TASTE; MYALGIA; NAUSEA; OBESITY; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; THORAX PAIN; UNSPECIFIED SIDE EFFECT; VOMITING; ADULT; ANEMIA, IRON-DEFICIENCY; DEFICIENCY; HEMOSTASIS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; ANEMIA, IRON-DEFICIENCY; HEMOSTASIS; HUMANS; IRON;

EID: 84928963582     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1401038     Document Type: Review

References (78)

1. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr 2009;12:444-54.
2. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell 2010;142:24-38.
3. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23.
4. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010;116:4754-61.
5. Goodnough LT, Schrier SL. Evaluation and management of anemia in the elderly. Am J Hematol 2014;89:88-96.
6. Macdougall IC. Iron supplementation in nephrology and oncology: what do we have in common Oncologist 2011;16:Suppl 3:25-34.
7. Ferrucci L, Semba RD, Guralnik JM, et al. Proinflammatory state, hepcidin, and anemia in older persons. Blood 2010;115:3810-6.
8. Marković M, Majkić-Singh N, IgnjatovićS, Singh S. Reticulocyte haemoglobin content vs. soluble transferrin receptor and ferritin index in iron deficiency anaemia accompanied with inflammation. Int J Lab Hematol 2007;29:341-6.
9. Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol 2013;161:639-48.
10. Schrier SL. Causes and diagnosis of iron deficiency anemia in the adults. 2014 (http://www.uptodate.com/contents/causes-and-diagnosis-of-iron-deficiency-anemia-in-the-adult).
11. DeLoughery TG. Microcytic anemia. N Engl J Med 2014;371:1324-31.
12. Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol 2012;156:588-600.
13. Powers JM, Buchanan GR. Diagnosis and management of iron deficiency anemia. Hematol Oncol Clin North Am 2014;28:729-45.
14. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 2014;123:615-24.
15. Stevens GA, Finucane MM, De-Regil LM, et al. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995-2011: a systematic analysis of population-representative data. Lancet Glob Health 2013;1(1):e16-e25.
16. Pasricha SR, Drakesmith H, Black J, Hipgrave D, Biggs BA. Control of iron deficiency anemia in low- and middle-income countries. Blood 2013;121:2607-17.
17. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.
18. Camaschella C. Iron and hepcidin: a story of recycling and balance. Hematology Am Soc Hematol Educ Program 2013;2013:1-8.
19. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011;117(25):e218-e225.
20. Traglia M, Girelli D, Biino G, et al. Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet 2011;48:629-34.
21. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014;46:678-84.
22. Mastrogiannaki MMP, Matak P, Peyssonnaux C. The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions. Blood 2013;122:885-92.
23. Zhang AS, Anderson SA, Wang J, et al. Suppression of hepatic hepcidin expression in response to acute iron deprivation is associated with an increase of matriptase-2 protein. Blood 2011;117:1687-99.
24. Goenka MK, Majumder S, Goenka U. Capsule endoscopy: present status and future expectation. World J Gastroenterol 2014;20:10024-37.
25. Mustafa BF, Samaan M, Langmead L, Khasraw M. Small bowel video capsule endoscopy: an overview. Expert Rev Gastroenterol Hepatol 2013;7:323-9.
26. Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf 2013;4:125-33.
27. Jonker FA, Calis JC, Phiri K, et al. Real-time PCR demonstrates Ancylostoma duodenale is a key factor in the etiology of severe anemia and iron deficiency in Malawian pre-school children. PLoS Negl Trop Dis 2012;6(3):e1555.
28. Friedman JF, Kanzaria HK, McGarvey ST. Human schistosomiasis and anemia: the relationship and potential mechanisms. Trends Parasitol 2005;21:386-92.
29. Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood 2014;123:326-33.
30. Bach V, Schruckmayer G, Sam I, Kemmler G, Stauder R. Prevalence and possible causes of anemia in the elderly: a crosssectional analysis of a large European university hospital cohort. Clin Interv Aging 2014;9:1187-96.
31. Aigner E, Feldman A, Datz C. Obesity as an emerging risk factor for iron deficiency. Nutrients 2014;6:3587-600.
32. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 2011;8:485-93.
33. Cohen-Solal A, Damy T, Terbah M, et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail 2014;16:984-91.
34. Jankowska EA, Malyszko J, Ardehali H, et al. Iron status in patients with chronic heart failure. Eur Heart J 2013;34:827-34.
35. Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008;40:569-71.
36. Du X, She E, Gelbart T, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008;320:1088-92.
37. Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008;8:502-11.
38. De Falco L, Sanchez M, Silvestri L, et al. Iron refractory iron deficiency anemia. Haematologica 2013;98:845-53.
39. Heeney MM, Finberg KE. Iron-refractory iron deficiency anemia (IRIDA). Hematol Oncol Clin North Am 2014;28:637-52.
40. Nai A, Pagani A, Silvestri L, et al. TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Blood 2011;118:4459-62.
41. Benyamin B, Ferreira MA, Willemsen G, et al. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet 2009;41:1173-5.
42. Tanaka T, Roy CN, Yao W, et al. A genome-wide association analysis of serum iron concentrations. Blood 2010;115:94-6.
43. An P, Wu Q, Wang H, et al. TMPRSS6, but not TF, TFR2 or BMP2 variants are associated with increased risk of iron-deficiency anemia. Hum Mol Genet 2012;21:2124-31.
44. Warsch S, Byrnes J. Emerging causes of iron deficiency anemia refractory to oral iron supplementation. World J Gastrointest Pharmacol Ther 2013;4:49-53.
45. Stein J, Stier C, Raab H, Weiner R. Review article: the nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther 2014;40:582-609.
46. Obinwanne KM, Fredrickson KA, Mathiason MA, Kallies KJ, Farnen JP, Kothari SN. Incidence, treatment, and outcomes of iron deficiency after laparoscopic Roux-en-Y gastric bypass: a 10-year analysis. J Am Coll Surg 2014;218:246-52.
47. Franceschi F, Zuccalà G, Roccarina D, Gasbarrini A. Clinical effects of Helicobacter pylori outside the stomach. Nat Rev Gastroenterol Hepatol 2014;11:234-42.
48. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013;108:656-76.
49. Murray JA, McLachlan S, Adams PC, et al. Association between celiac disease and iron deficiency in Caucasians, but not non-Caucasians. Clin Gastroenterol Hepatol 2013;11:808-14.
50. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48.
51. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration Blood 2006;107:1747-50.
52. Brugnara C, Mohandas N. Red cell indices in classification and treatment of anemias: from M.M. Wintrobes's original 1934 classification to the third millennium. Curr Opin Hematol 2013;20:222-30.
53. Camaschella C. How I manage patients with atypical microcytic anaemia. Br J Haematol 2013;160:12-24.
54. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014;29:2075-84.
55. Sazawal S, Black RE, Ramsan M, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet 2006;367:133-43.
56. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012;338:768-72.
57. Clark MA, Goheen MM, Fulford A, et al. Host iron status and iron supplementation mediate susceptibility to erythrocytic stage Plasmodium falciparum. Nat Commun 2014;5:4446.
58. Atkinson SH, Armitage AE, Khandwala S, et al. Combinatorial effects of malaria season, iron deficiency, and inflammation determine plasma hepcidin concentration in African children. Blood 2014;123:3221-9.
59. Kortman GA, Raffatellu M, Swinkels DW, Tjalsma H. Nutritional iron turned inside out: intestinal stress from a gut microbial perspective. FEMS Microbiol Rev 2014;38:1202-34.
60. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011;118:3222-7.
61. Pasricha SR Sr, Low M, Thompson J, Farrell A, De-Regil LM. Iron supplementation benefits physical performance in women of reproductive age: a systematic review and meta-analysis. J Nutr 2014;144:906-14.
62. Bregman DB, Goodnough LT. Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Ther Adv Hematol 2014;5:48-60.
63. van Santen S, de Mast Q, Oosting JD, van Ede A, Swinkels DW, van der Ven AJ. Hematologic parameters predicting a response to oral iron therapy in chronic inflammation. Haematologica 2014;99(9):e171-e173.
64. Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2014;54:306-15.
65. Vadhan-Raj S, Strauss W, Ford D, et al. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol 2014;89:7-12.
66. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010;2010:338-47.
67. Bager P, Dahlerup JF. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. J Crohns Colitis 2010;4:427-30.
68. Reinisch W, Chowers Y, Danese S, et al. The management of iron deficiency in inflammatory bowel disease - an online tool developed by the RAND/UCLA appropriateness method. Aliment Pharmacol Ther 2013;38:1109-18.
69. Bailie GR, Larkina M, Goodkin DA, et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2013;28:2570-9.
70. Rampton DFJ, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014;99:1671-6.
71. Gupta A, Manaktala U, Rathore AM. A randomised controlled trial to compare intravenous iron sucrose and oral iron in treatment of iron deficiency anemia in pregnancy. Indian J Hematol Blood Transfus 2014;30:120-5.
72. Comin-Colet J, Lainscak M, Dickstein K, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J 2013;34:30-8.
73. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657-68.
74. Auerbach M, Strauss W, Auerbach S, Rineer S, Bahrain H. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. Am J Hematol 2013;88:944-7.
75. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. London: European Medicines Agency, 2013 (http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2013/06/WC500144874.pdf).
76. Bircher AJAM, Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am 2014;34:707-23.
77. Fernández-Real JM, Manco M. Effects of iron overload on chronic metabolic diseases. Lancet Diabetes Endocrinol 2014;2:513-26.
78. Fishbane S, Hazzan AD. Anaemia: FIND-CKD: intravenous iron in predialysis CKD. Nat Rev Nephrol 2014;10:488-9.